Pregabalin in Chronic Post-thoracotomy Pain 1659-1661
Dr. Ashvind Bawa,
Assistant Professor, Department of Surgery, Dayanand Medical College & Hospital,
Civil Lines, Ludhiana , Punjab, India.
Phone: +91-97814-50786, E-mail: firstname.lastname@example.org
Introduction: Chronic post thoracotomy pain (CPP) has very high incidence and therefore it needs attention. Usually, it is burning, dysaesthetic and aching in nature and it displays many features of neuropathic pain. No one technique of thoracotomy has been shown to reduce the incidence of chronic post thoracotomy pain.
Objectives: To evaluate the efficacy and safety of pregabalin in patients with chronic post thoracotomy pain.
Methods: This prospective, randomized study was conducted on 50 consenting patients who underwent posterolateral thoracotomy. 25 patients were given pregabalin for 21 days (Group A). Another 25 were given diclofenac sodium (Group B) on demand and they escaped treatment. Visual Analogue Scale (VAS) scoring was performed on days 0, 1 and 7, then follow up was done at 3, 6, 12 and 24 weeks. The data was analyzed by using T-test and Chi- square test for various variables.
Results: The pain VAS scores in group A were significantly low at all observation points except on day 0, day 1 and day 7 post-operatively, when the difference in pain scores in both the groups were comparable. The overall pain scores of group A were comparable at day 0, day 1 and at day 7 as compared to those of group B (p>0.9). Pain was significantly low at three weeks (p<0.05). Pain scores of group A were significantly low at 6 weeks,12 weeks and 24 weeks as compared to those of group B (p<0.001) and the difference was statistically significant. No significant adverse reactions were observed during study period.
Conclusion: Pregabalin is a safe and an effective adjuvant which is used for reducing the chronic post thoracotomy pain, which has no side effects and a high patient compliance. These results should be supported with multidisciplinary studies with larger sample sizes and longer follow-ups.